upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism

upLIFT: A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism (Tumor HI)

IDENTIFIER (ClinicalTrials.gov): NCT06881992

DRUG/TREATMENT: Ersodetug

PHASE: 3

STATUS: Recruiting

SPONSOR: Rezolute

DESCRIPTION:

upLIFT Study Interim Update June 2, 2026

Rezolute has shared an interim update from the upLIFT clinical trial, which is studying an investigational therapy called ersodetug for people with Tumor Hyperinsulinism (Tumor HI).

The study is now halfway through enrollment, with 8 of a planned 16 participants enrolled. Of those 8 participants, 6 have met the study's primary endpoint — a reduction of at least 50% in the intravenous (IV) glucose needed to maintain stable blood sugar levels. All 6 were also able to discontinue IV glucose entirely while receiving ersodetug. No drug-related side effects have been reported to date.

Participants who complete the initial 8-week treatment period have the option to continue in a 6-month extended phase. Full topline results from the completed study are expected in the second half of 2026.

Please note: ersodetug is an investigational therapy that has not yet been reviewed or approved by any regulatory health authority.

Read the full press release here.

Rezolute is a late-stage rare disease company focused on substantially improving the quality of life for individuals living with hyperinsulinism (HI) and is now enrolling participants in the upLIFT study, a phase 3 clinical trial that is testing whether or not a new therapy, called ersodetug, can safely reduce hypoglycemia in adults with tumor HI.

In tumor HI, certain tumors (lumps or abnormal cell growths) in the pancreas or other parts of the body make too much insulin or a similar protein called insulin-like growth factor-2 (IGF-2). Insulinomas are a rare type of neuroendocrine tumor that usually form from the insulin-secreting cells in the pancreas. Non-islet cell tumor hypoglycemia (sometimes called “Doege-Potter syndrome” or “paraneoplastic hypoglycemia”) is a rare condition where certain tumors outside the pancreas make too much hormone growth factors that can act like insulin. Both types of tumors can lead to very low blood sugar levels, a severe and potentially life-threatening complication of overactivation of the insulin receptor. 

Hypoglycemia can result in neurologic and cognitive problems as well as other serious health complications and may make it hard for people with tumor HI to stay healthy enough to continue their cancer treatments. We know that patients facing these complications often have complex needs and limited treatment options. We believe collaboration between patient advocacy organizations is essential to ensure patients receive the best possible support and access to care.

This study is open to people 18 and older who have a type of tumor that causes tumor HI and are still experiencing frequent, serious low blood sugar levels, even with standard treatment. To learn more about the study or potential participation please talk to your doctor or visit upliftstudy.com or clinicaltrials.gov. You may also contact patient affairs via email at patient-affairs@rezolutebio.com for further assistance, if needed. Please note that ersodetug is still under investigation and has not been approved by any health authority.  

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to  view this trial here.

CONTACT

Name: Rezolute Clinical Trial

Phone Number: 650-206-4507

Email: patient-affairs@rezolutebio.com (primary contact). You may also reach out to clinicaltrials@rezolutebio.com.

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.